Campion TR Jr, Sholle ET, Davila MA Jr Generalizable Middleware to Support Use of REDCap Dynamic Data Pull for Integrating Clinical and Research Data. AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:76-81. eCollection 2017.
Guttmacher AE, Collins FS, Carmona RH The family history--more important than ever. N Engl J Med. 2004 Nov 25;351(22):2333-6. doi: 10.1056/NEJMsb042979. No abstract available.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008 Apr;19(4):385-97. doi: 10.1007/s00198-007-0543-5. Epub 2008 Feb 22.
Karnes JH, Van Driest S, Bowton EA, Weeke PE, Mosley JD, Peterson JF, Denny JC, Roden DM Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med. 2014 Mar-Apr;6(2):125-35. doi: 10.1002/wsbm.1255. Epub 2013 Dec 6. Erratum In: Wiley Interdiscip Rev Syst Biol Med. 2015 May-Jun;7(3):139.
Li M, Scaiano M, El Emam K, Malin BA Efficient Active Learning for Electronic Medical Record De-identification. AMIA Jt Summits Transl Sci Proc. 2019 May 6;2019:462-471. eCollection 2019.
Pulley J, Clayton E, Bernard GR, Roden DM, Masys DR Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci. 2010 Feb;3(1):42-8. doi: 10.1111/j.1752-8062.2010.00175.x.
Pulley JM, Brace MM, Bernard GR, Masys DR Attitudes and perceptions of patients towards methods of establishing a DNA biobank. Cell Tissue Bank. 2008 Mar;9(1):55-65. doi: 10.1007/s10561-007-9051-2. Epub 2007 Oct 25.
Pulley JM, Harris PA, Yarbrough T, Swafford J, Edwards T, Bernard GR An informatics-based tool to assist researchers in initiating research at an academic medical center: Vanderbilt Customized Action Plan. Acad Med. 2010 Jan;85(1):164-8. doi: 10.1097/ACM.0b013e3181c481bf.
Xia W, Heatherly R, Ding X, Li J, Malin BA R-U policy frontiers for health data de-identification. J Am Med Inform Assoc. 2015 Sep;22(5):1029-41. doi: 10.1093/jamia/ocv004. Epub 2015 Apr 24.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.